GlassScriptPhysician profile
David Lee Schoenfish
NPI 1154883437
$24,716.57
in general payments reported to CMS, 2019-2025
68 companies · $4,659 in 2025
The $4,659 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,376 · 2022: $4,667 · 2023: $5,155 · 2024: $4,860 · 2025: $4,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,561.43 |
| Education | $112.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,756.28 | 2021-2025 | |
| Biogen, INC. | $2,561.35 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Lilly USA, LLC | $2,088.90 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Novartis Pharmaceuticals Corporation | $1,782.67 | 2021-2025 | |
| Lundbeck LLC | $1,702.44 | 2021-2025 | Vyepti, Rexulti |
| Pfizer INC. | $958.03 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $720.27 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $614.47 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Amneal Pharmaceuticals LLC | $612.12 | 2022-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $604.78 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Harmony Biosciences LLC | $576.57 | 2022-2025 | Wakix |
| Emd Serono, INC. | $560.99 | 2021-2025 | Mavenclad |
| Axsome Therapeutics, INC. | $488.69 | 2023-2025 | Symbravo, Sunosi |
| Sunovion Pharmaceuticals INC. | $436.95 | 2021-2022 | |
| Eisai INC. | $424.31 | 2021-2025 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schoenfish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.